Based on the molecular mechanism, a classification of BRAF mutations identified in cancer samples has been proposed (Dankner et al., 2018): class 1 mutations mimic the phosphorylation of the activation loop and thereby lead to aberrant activation of the kinase domain. This evidence concerns the gene BRAF and cancer.